Literature DB >> 24189428

Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome.

Amr Selim Abu Lila1, Masako Ichihara, Taro Shimizu, Tatsuhiro Ishida, Hiroshi Kiwada.   

Abstract

We have reported that PEGylated liposomes lose their long-circulating properties when injected twice into the same animal within a certain interval (the accelerated blood clearance (ABC) phenomenon). We assumed that this phenomenon was triggered via the abundant secretion of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) in response to the first dose of PEGylated liposomes and that the spleen played an important role in the production of anti-PEG IgM. However, no direct evidence has yet confirmed this suspicion. In the current study, we verified, both in vitro and ex vivo, that spleen cells are indeed responsible for the production of anti-PEG IgM in response to PEGylated liposomes. In this study, spleen cells obtained from either naïve mice or mice pre-treated with PEGylated liposomes induced the production of anti-PEG IgM in a dose- and time-dependent manner, upon incubation with PEGylated liposomes. In addition, we confirmed that among the different fractions of splenic B cells, IgM-positive B cells, rather than CD45R-positive or CD19-positive splenic B cells, which are presumed to be the marginal zone B (MZB) cells, are the major cells producing anti-PEG IgM in the response to stimulation by PEGylated liposomes. These results may provide new insights into the mechanisms underlying the anti-PEG IgM production in response to the stimulation by PEGylated liposomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24189428     DOI: 10.1248/bpb.b13-00562

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

1.  Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells.

Authors:  Joy Wolfram; Krishna Suri; Yi Huang; Roberto Molinaro; Carlotta Borsoi; Bronwyn Scott; Kathryn Boom; Donatella Paolino; Massimo Fresta; Jianghua Wang; Mauro Ferrari; Christian Celia; Haifa Shen
Journal:  J Microencapsul       Date:  2014-03-24       Impact factor: 3.142

2.  A Cell Assay for Detecting Anti-PEG Immune Response against PEG-Modified Therapeutics.

Authors:  Taro Shimizu; Amr S Abu Lila; Mizuki Awata; Yukiyo Kubo; Yu Mima; Yosuke Hashimoto; Hidenori Ando; Keiichiro Okuhira; Yu Ishima; Tatsuhiro Ishida
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

Review 3.  Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.

Authors:  Mauro Cataldi; Chiara Vigliotti; Teresa Mosca; MariaRosaria Cammarota; Domenico Capone
Journal:  Int J Mol Sci       Date:  2017-06-10       Impact factor: 5.923

Review 4.  Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies.

Authors:  Helena Freire Haddad; Jacqueline A Burke; Evan A Scott; Guillermo A Ameer
Journal:  Regen Eng Transl Med       Date:  2021-03-25

5.  Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review).

Authors:  Chuang Yang; Zhong-Xue Fu
Journal:  Biomed Rep       Date:  2014-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.